Login to Your Account

Derma Has Foot in Door in Chronic Wound Care Race

By Catherine Shaffer
Staff Writer

Thursday, February 7, 2013

Derma Sciences Inc., of Princeton, N.J., is taking an important step in development of a therapy for a tough indication – diabetic foot ulcer. It began enrolling patients in the first of two Phase III trials of its topical drug candidate, DSC127.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription